Navigation Links
Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients

ents," he added.

Data analysis surrounding the mode of action of this novel treatment strategy was also presented at the AAN, in which researchers attributed the benefit of the combination of therapies to the combined anti-inflammatory effect of COPAXONE(R) and mitoxantrone.

"These data shed new light on the concept of treating MS by first suppressing the auto-aggressive immune system with an immunosuppressant, and then favorably modifying its activity with an immunomodulator such as COPAXONE(R)," said Amit Bar-Or, M.D., FRCPC, assistant professor, Director of the Experimental Therapeutics at the Montreal Neurological Institute (MNI) and primary investigator of the immunological study.

About the Analyses

The analysis, Reductions in MRI Disease Activity and Relapse Rates Observed after Induction of Short-term Immunosuppression with Mitoxantrone Followed by Long-term Glatiramer Acetate (GA) Are Maintained at 24 Months in Patients with Relapsing Remitting Multiple Sclerosis (RRMS), determined that the increased efficacy and the safety observed at 15 months with COPAXONE(R) after brief mitoxantrone therapy was maintained with continued COPAXONE(R) at 24 months. The original study included RRMS patients (n=40), ages 18-55, who had at least one Gd-enhancing lesion at the time of the screening MRI and an Expanded Disability Status Scale (EDSS) score of <= 6.5. Brain MRIs were performed at screening and months six, nine, 12 and 15.

The abstract is accessible online at: http://www.abstracts2view.com/aan2007boston/view.php?nu=AAN07L_P06.096 &terms. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

Patients were randomized to receive 3 monthly intravenous (IV) infusions of mitoxantrone (36 mg/m(2) total) followed by a 2-week washout, then COPAXONE(R) 20 mg/d for 12.5 months (n=21) or COPAXONE(R) 20 mg/d alone (n=19) for 15 months.

In t
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
2. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
3. Data on Higher Dose of Copaxone and Data Showing Copaxone is Most Cost Effective
4. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
5. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
6. Point of Care Strep Tests Speed Treatment, Lower Costs
7. Rapid HIV Testing Increases Possibility of Treatment
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015  Delays in ... projects can slow down the decision-making process, resulting ... therefore, absolutely critical for biopharmaceutical companies to develop ... approval process for quicker and more meaningful insights. ... Best Practices, LLC, nearly three-quarters of benchmarked study ...
(Date:8/28/2015)... 2015 Research and ... of the "12th Annual Report and Survey ... to their offering. The 2015 12th ... and Production is the most recent study of ... projected future capacity and production. The report contains ...
(Date:8/28/2015)... 28, 2015 Research ... of the "Investigation Report on China,s Insulin ... Developed by Novo Nordisk, insulin aspart ... important drug for the treatment of diabetes. Compared ... acting insulin analog, starts working fast and reports ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... issued today a shareholders, letter discussing the results of its fiscal ... Dear Imagenetix shareholder - Following ... we commence the new fiscal year, I would like to address ...   Over the past few years our primary strategy ...
... July 12, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... 1 clinical trial of APD811, an orally bioavailable agonist ... treatment of pulmonary arterial hypertension, or PAH. ... tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 ...
Cached Medicine Technology:Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 2Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 4
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional ... from Administrative assistant to Executive Assistant to CEO Mitch Gould for Nutritional Products ... focused on your goals. Kathleen graduated from Florida State University with a ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been ... Place, N.Y. "I specialize in manual therapy, and my invention will provide headache ... used for additional muscle dysfunction throughout the body." , They developed THE RELIEVER ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President of ... increase acceptance of the chiropractic field in the military. All too often VA hospitals ... Chiropractic was made available to the VA program over a decade ago, the reality ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... ProDrop ... X . Each preset contains 15 seconds of unique footage that users can shrink ... rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, ...
Breaking Medicine News(10 mins):Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... the first time, results on the impact of gaming devices ... at the EULAR 2011 Annual Congress. Data comparing two schools ... of pain following long term use of gaming devices and ... joint health. , The study, involving 257 students, highlights that ...
... , WEDNESDAY, May 25 (HealthDay News) --,The ability of ... level of commitment in their romantic relationships can be traced ... finds. Researchers asked 78 people aged 20 or 21 ... their relationship. The researchers already had data on the ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, ... doctors a community has, especially ones who are actually ... are, a new Dartmouth study suggests. Those ... death rate among local elders, the researchers found. ...
... Goodwin HealthDay Reporter , TUESDAY, May 24 (HealthDay ... pitched sounds when underwater than they can while on terra ... with their bones rather than through the normal pathways of ... humans hear above or below water differs; that difference means ...
... Clinical trials for a new bladder cancer therapy show ... the breakthrough using the drug Urocidin follows thirty years ... am optimistic about the results of the trial," says ... at Queen,s University and director of the Queen,s University ...
... News) -- Losing weight may not be required to lower ... Rather, the study found, small dietary changes can make a ... among blacks. For the study, published online May 18 ... researchers put 69 overweight people at risk for diabetes on ...
Cached Medicine News:Health News:Children experience wrist and finger pain when using gaming devices and mobile phones over time 2Health News:Capacity for Commitment May Start in Early Childhood 2Health News:More Primary Care Docs in a Community Equals Healthier Seniors 2Health News:More Primary Care Docs in a Community Equals Healthier Seniors 3Health News:Underwater, Humans Hear Through Their Bones 2Health News:Underwater, Humans Hear Through Their Bones 3Health News:New made-in-Canada therapy for bladder cancer shows promising results 2Health News:Simply Eating Less Fat May Cut Diabetes Risk 2
... Quality Analysis System) developed by Pablo Artal, ... first diagnostic tool for ophthalmology that provides ... system. Never before has an ophthalmologist had ... quality of vision. , ,OQAS works by ...
... -Chagas is an in-vitro diagnostic test ... to Trypanosoma cruzi in human serum/plasma. ... particle-agglutination assay using gelatin particles coated ... coated gelatin particles are agglutinated in ...
Inquire...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Medicine Products: